Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | DCUN1D2 | Q6PH85 | 1/20 | 0.33 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366164 | 1.00 | TRPA1 (0.35) | TRPA1ALDH1A1TSHRDCUN1D1DCUN1D2 | |
| SCHEMBL6961815 | 0.88 | TDP1 (0.39) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL1773521 | 0.86 | FYN (0.39) | TSHRDCUN1D1DCUN1D2AGTR1AGTR2 | |
| SCHEMBL6955274 | 0.85 | GP6 (0.34) | TSHRDCUN1D1DCUN1D2GP6AGTR1 | |
| SCHEMBL6962635 | 0.84 | AKT1 (0.36) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL6955822 | 0.84 | TP53 (0.41) | AGTR1AGTR2 | |
| SCHEMBL1132111 | 0.84 | TAAR1 (0.43) | ALDH1A1 | |
| SCHEMBL21034528 | 0.84 | DCUN1D1 (0.33) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL6957576 | 0.84 | GP6 (0.36) | GP6AGTR1AGTR2 | |
| SCHEMBL8674236 | 0.84 | FOLH1 (0.33) | TRPA1ALDH1A1TSHRDCUN1D1DCUN1D2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113993851-B | Valsartan refining method | 浙江华海药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023181045-A1 | PROCESS FOR THE PREPARATION OF CARCINOGENIC AZIDO IMPURITIES FREE LOSARTAN AND SALTS THEREOF | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| CN-113727976-B | Refining method of valsartan compound | 浙江华海药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-113993851-A | Valsartan refining method | 浙江华海药业股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113727976-A | Refining method of valsartan compound | 浙江华海药业股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021022516-A1 | VALSARTAN REFINEMENT METHOD | 浙江华海药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| WO-2020252662-A1 | METHOD FOR REFINING VALSARTAN COMPOUND | 浙江华海药业股份有限公司 | 2020-12-24 | — | — | WO | disclosed |
| EP-2194050-A1 | A new process for the preparation of irbesartan | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2010-06-09 | — | — | EP | disclosed |
| US-20080275096-A1 | Process for the preparation of valsartan | HAREL ZVI | 2008-11-06 | — | — | US | disclosed |
| US-7378531-B2 | Process for the preparation of valsartan | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-0711762-B1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6214999-B1 | A BROMINATING AGENT IS REACTED IN A 2 PHASE MEDIUM, UNDER EFFECT PHOTO-IRRADIATION WITH BIPHENYL DERIVATIVE | SANOFI-SYNTHELABO (FR) | 2001-04-10 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-1032557-A1 | METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025681-A1 | METHOD FOR PREPARING BROMOMETHYL-BIPHENYL DERIVATIVES | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| US-5326776-A | Tetrazoles | ABBOTT LABORATORIES (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1993017681-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275096-A1 | Process for the preparation of valsartan | REN, AGT, AVPR2 | TRPA1 4494/4885ALDH1A1 2835/4885TSHR 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.